IART Quote, Financials, Valuation and Earnings

LeMaitre Vascular has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 18.39%. Integra Lifesciences Holdings's return on equity of -1.88% beat LeMaitre Vascular's return on equity of 13.74%.

Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 33.27%. On the other hand LeMaitre Vascular has an analysts' consensus of $104.50 which suggests that it could grow by 26.5%. Given that Integra Lifesciences Holdings has higher upside potential than LeMaitre Vascular, analysts believe Integra Lifesciences Holdings is more attractive than LeMaitre Vascular.

Integra Lifesciences Holdings has a beta of 1.152, which suggesting that the stock is 15.175% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.388%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.87% to investors and pays a quarterly dividend of $0.20 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $382.7M, which are larger than LeMaitre Vascular quarterly revenues of $59.9M. Integra Lifesciences Holdings's net income of -$25.3M is lower than LeMaitre Vascular's net income of $11M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while LeMaitre Vascular's PE ratio is 41.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 8.34x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 6.22%. Integra Lifesciences Holdings's return on equity of -1.88% beat Insulet's return on equity of 36.9%.

Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 33.27%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that Integra Lifesciences Holdings has higher upside potential than Insulet, analysts believe Integra Lifesciences Holdings is more attractive than Insulet.

Integra Lifesciences Holdings has a beta of 1.152, which suggesting that the stock is 15.175% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $382.7M, which are smaller than Insulet quarterly revenues of $569M. Integra Lifesciences Holdings's net income of -$25.3M is lower than Insulet's net income of $35.4M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 13.56%. Integra Lifesciences Holdings's return on equity of -1.88% beat Teleflex's return on equity of 3.41%.

Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 33.27%. On the other hand Teleflex has an analysts' consensus of $151.02 which suggests that it could grow by 33.27%. Given that Teleflex has higher upside potential than Integra Lifesciences Holdings, analysts believe Teleflex is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.152, which suggesting that the stock is 15.175% more volatile than S&P 500. In comparison Teleflex has a beta of 1.080, suggesting its more volatile than the S&P 500 by 8.03%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 1.2% to investors and pays a quarterly dividend of $0.34 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Integra Lifesciences Holdings quarterly revenues are $382.7M, which are smaller than Teleflex quarterly revenues of $700.7M. Integra Lifesciences Holdings's net income of -$25.3M is lower than Teleflex's net income of $95M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Teleflex's PE ratio is 35.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 1.76x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of -30.29%. Integra Lifesciences Holdings's return on equity of -1.88% beat Treace Medical Concepts's return on equity of -47.17%.

Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 33.27%. On the other hand Treace Medical Concepts has an analysts' consensus of $10.02 which suggests that it could grow by 71.23%. Given that Treace Medical Concepts has higher upside potential than Integra Lifesciences Holdings, analysts believe Treace Medical Concepts is more attractive than Integra Lifesciences Holdings.

Integra Lifesciences Holdings has a beta of 1.152, which suggesting that the stock is 15.175% more volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

Integra Lifesciences Holdings quarterly revenues are $382.7M, which are larger than Treace Medical Concepts quarterly revenues of $52.6M. Integra Lifesciences Holdings's net income of -$25.3M is lower than Treace Medical Concepts's net income of -$15.9M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 1.73x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.